Skip to main content

A consumer resource from PeRx

Six sourcing and quality questions to ask before starting peptide therapy.

What patients can verify about pharmacy licensing, ingredient sourcing, batch testing and follow-up.

HHS said one aim of its new peptide compounding policy is to steer patients away from research-use-only peptides supplied by foreign manufacturers. Sellers offering substances labeled “research use only” remain easy to find alongside licensed clinical programs.

PeRx encourages consumers to ask the following before beginning any peptide-related treatment.

The checklist

Six sourcing and quality questions for consumers

  1. 1

    Which licensed pharmacy prepares and dispenses the medication?

    Consumers should be able to verify the pharmacy’s license with the relevant state board of pharmacy. A Section 503A compounding pharmacy should not be described as FDA approved.

  2. 2

    Is the medication prescribed for me, by a named, licensed clinician?

    Federal law requires a valid patient-specific prescription for 503A compounding, though a prescription alone does not make compounding a given substance lawful. A product shipped without one is a warning sign.

  3. 3

    Is the regulatory status described accurately?

    “Compounded,” “covered by an enforcement policy” and “FDA approved” mean different things. The new HHS policy applies only to specific peptides, forms and routes, under set conditions, and not every compounded product relies on it. A provider should be able to explain plainly which rules apply to a given product.

  4. 4

    Where does the active ingredient come from?

    Under Section 503A, bulk ingredients must come from an FDA-registered manufacturer and arrive with a valid certificate of analysis. Consumers can ask whether the pharmacy can name the original manufacturer and show that certificate.

  5. 5

    What testing was done on my batch?

    Testing of the raw ingredient and testing of the finished product are different. Identity, potency, sterility and endotoxin testing are separate measures, and a certificate of analysis is meaningful only if it shows what was tested for the specific lot.

  6. 6

    Who monitors me after the product ships?

    A responsible provider schedules follow-up, explains how to report side effects, including to FDA’s MedWatch program, and says when treatment should stop.

Our practices

How PeRx handles this.

  • Pharmacies and ingredients

    PeRx dispenses only through state-licensed 503A pharmacies, which source active ingredients from FDA-registered manufacturers with a certificate of analysis for each lot.

  • Testing and certificates

    Each finished lot is tested by an independent laboratory for potency, sterility, endotoxins and pH, and patients can request the certificate for the lot they receive by calling the number printed on the vial.

  • Pharmacy vetting

    PeRx vets each partner pharmacy by verifying its license in every state it ships to, reviewing its inspection records, reviewing batch documentation and conducting periodic audits or site visits.

How to use these questions

The questions build on the physician-reviewed checklist PeRx published for consumers evaluating online peptide providers. They are offered as general educational information for anyone considering peptide therapy, regardless of which provider they choose. They are not intended to diagnose a condition, recommend a particular treatment or replace a consultation with a qualified healthcare professional.

Read the peptide provider checklist

Compounded drugs are not FDA approved. HHS's enforcement discretion policy and FDA advisory committee recommendations do not constitute FDA approval and do not add any substance to the Section 503A Bulks List.